BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock

With a forward P/E of 14.45x and upside potential of 59.60%, Boston Scientific Corporation (NYSE: BSX ) ranks among the top 10 lowest forward P/E stocks in the S&P 500 .

A dose bottle of the medication is in the medical tech's hand

Boston Scientific Corporation (NYSE:BSX) has seen a sharp de-rating in 2026, with shares down nearly 50% year-to-date as of June 8, 2026, even as the vast majority of covering analysts maintain bullish ratings on the stock.

The pressure point is Boston Scientific Corporation (NYSE:BSX)'s Watchman left atrial appendage closure franchise, where management recently signaled reduced growth expectations over the next couple of quarters.

On June 3, 2026, BTIG analyst Marie Thibault cut the firm's price target on Boston Scientific Corporation (NYSE:BSX) to $65 from $80, keeping a "Buy" rating, after updating the firm's forecast to reflect those comments, made at a sell-side conference. BTIG said visibility is limited for now and framed its stance as cautious, modeling flattish Watchman sales in the second and third quarters, a slight sequential uptick in the fourth quarter, and a mild, gradual recovery through 2027.

On June 1, 2026, Canaccord also trimmed its price target, to $70 from $71, while keeping a "Buy" rating. The firm updated its model to account for Watchman slowdowns in both 2026 and 2027, which it said carry negative implications for its revenue and EPS estimates.

Despite the target cuts, both firms held their bullish ratings, reflecting the broader Wall Street view on Boston Scientific Corporation (NYSE:BSX).

Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.